Item 18.1

Recommendations for NHS Vale of York CCG from York and Scarborough Medicines Commissioning Committee March 2016

	Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential cost impact
1	Clindamycin 1% gel	Acne	Not approved	Topical antibiotic therapy alone not clinically appropriate	Nil	Black	Nil
2	Erythromycin 2% solution	Acne	Not approved	Topical antibiotic therapy alone not clinically appropriate	Nil	Black	Nil
3	Financea	Acne	Not approved	Not clinically appropriate for acne treatment	Nil	Black	Nil
4	Yasmin (or branded generic equivalents)	Acne	Not approved	Not cost effective	Nil	Black	Nil
5	Ezetimibe for treating primary heterozygous- familial and non-familial hypercholesterolaemia <u>TA385</u>	Hypercholester- olaemia	Approved	NICE approved	As per NICE guidance	Green	NICE advise: "No resource impact is anticipated because the recommendations have not significantly changed from the previous NICE guidance".
6	TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis <u>TA383</u>	Ankylosing spondylitis	Approved	NICE approved	As per NICE guidance	Red	£401,185

NHS Vale of York Clinical Commissioning Group

7	Develoille active	Custinumia	A	Fuinting a vision of	First lines		
/	Penicillamine	Cystinuria	Approved	Existing evidence	First line	Amber shared	Nil
				based treatment		care	
8	Tiopronin	Cystinuria	Approved	Evidence based	Second line	Red – hospital	Nil
				treatment	(unlicensed	only	
					treatment)		
9	Verteporfin photodynamic therapy	Treatment of	Not approved	Lack of clinical	Nil	Black	Nil
		central serous		evidence to			
	(VPDT)	chorioretinopathy		support			
		(CSCR)					
10	Sodium chloride 5%,	Corneal	Approved	Cost effective	As per existing	Amber specialist	Nil – cost saving
	sodium hyaluronate	oedema/Fuchs'		preparation	formulary status	recommendation	
	0.15% preservative-free	endothelial					
	eye drops (ODM5)	dystrophy					
11	Cefixime	For use in genito-	Approved	Confirmation of	Confirmation of	Red	Nil
		urinary medicine		formulary status	formulary status		
12	Demeclocycline	Infections	Approved	Confirmation of	Confirmation of	Red	Nil
				formulary status	formulary status		
13	Demeclocycline	SIADH	Approved	Confirmation of	Confirmation of	Amber specialist	Nil
				formulary status	formulary status	recommendation	
14	Minocycline	Acne	Not approved	Confirmation of	Confirmation of	Black	Nil
				formulary status	formulary status		
15	Sodium fusidate (oral	Infections	Approved	Confirmation of	Confirmation of	Amber specialist	Nil
	formulations)			formulary status	formulary status	recommendation	

ltem 18.1

			•			•	Item 18.1
16	Co-trimoxazole	Prophylaxis of infections e.g.	Approved	Confirmation of formulary status	Confirmation of formulary status	Amber specialist recommendation	Nil
		pneumocystis carinii		,	,		
17	Sulphadiazine	Toxoplasmosis	Approved	Confirmation of	Confirmation of	Red	Nil
				formulary status	formulary status		
18	Dapsone	Treatment of rare	Approved	Confirmation of	Confirmation of	Red	Nil
		infections		formulary status	formulary status		
19	Ciprofloxacin	Restricted as per	Approved	Confirmation of	Confirmation of	Green	Nil
		North Yorkshire Antimicrobial guidelines.		formulary status	formulary status		
20	Levofloxacin	For restricted use	Approved	Confirmation of	For occasional	Amber specialist	Nil
				formulary status	use where	recommendation	
					penicillin allergy exists		
21	Itraconazole	For use as per	Approved	Confirmation of	Confirmation of	Green	Nil
		North Yorkshire Antimicrobial		formulary status	formulary status		
		guidelines.					
22	Oseltamivir (Tamiflu)	For use when	Approved	Confirmation of	As per NICE	Green	Nil
		influenza virus circulating		formulary status	guidance		
23	Zanamavir	For use when	Approved	Confirmation of	As per NICE	Green	Nil
		influenza virus circulating		formulary status	guidance		
24	Diloxanide furoate	For the treatment	Approved	Confirmation of	Confirmation of	Red	Nil
		of amebiasis		formulary status	formulary status		
25	Praziquantal	For the treatment	Approved	Confirmation of	Confirmation of	Amber	Nil
		of protozoal infections		formulary status	formulary status		

NHS Vale of York Clinical Commissioning Group

ltem 18.1

26	Paraldehyde 50% in olive	For treatment of	Approved	Confirmation of	As per Sheffield	Amber shared	Nil
	oil enema 30ml	epilepsy		formulary status	treatment	care	
					guideline		
27	Slow sodium	For the	Approved	Confirmation of	Confirmation of	Green	Nil
		management of		formulary status	formulary status		
		low sodium levels					
28	Sildenafil / tadalafil for	For the	Approved	Confirmation of	As per formulary	Amber specialist	Nil
	priapism	management of		formulary status	statement	recommendation	
		priapism					
29	Palliative care – see list	Palliative care	Approved	Confirmation of	Confirmation of	See list	No significant
	of drugs in separate	treatments		formulary status	formulary status		change
	document			in line with newly	in line with newly		
				approved	approved		
				guideline	guideline		

Additional comments:

- It was agreed that all insulins would be classed as "green" with the exception of Degludec (amber) and Humulin R also known as U500 (red)
- Please see separate document for palliative care drugs approval available at <u>http://www.palliativecareguidelines.scot.nhs.uk/</u>